Skip to main content
Clinical Trials/NCT04754217
NCT04754217RecruitingNot Applicable

Valved Graft Post-Market Clinical Follow-up Study

Abbott Medical Devices48 sites in 10 countries260 target enrollmentStarted: July 13, 2021Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
260
Locations
48
Primary Endpoint
annualized event rate of all-cause mortality

Study Overview

Brief Summary

Multicenter, global, prospective, non-randomized, interventional, post-market trial. All subjects enrolled will receive an Abbott Valved Graft device.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • cardiac surgery including the implant of a VAVGJ or CAVGJ for native or prosthetic valve replacement

Exclusion Criteria

  • anticoagulation therapy intolerant
  • active endocarditis
  • anatomical or medical, surgical, psychological or social contraindications

Arms & Interventions

Group 2

CAVGJ

Intervention: CAVGJ (Device)

Group 1

VAVGJ

Intervention: VAVGJ (Device)

Outcomes

Primary Outcomes

annualized event rate of all-cause mortality

Time Frame: 5 Years

Primary Safety Endpoint

annualized event rate of reintervention

Time Frame: 5 Years

Primary Effectiveness Endpoint

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (48)

Loading locations...

Similar Trials